Video
Dr. Dreicer on the Optimal Use of Radium-223 in Prostate Cancer
Author(s):
Robert Dreicer, MD, professor, Department of Medicine, Division of Hematology/Oncology, University of Virginia Health System, discusses the optimal use of radium-223 dichloride (Xofigo) for patients with metastatic castration-resistant prostate cancer.
Robert Dreicer, MD, professor, Department of Medicine, Division of Hematology/Oncology, University of Virginia Health System, discusses the optimal use of radium-223 dichloride (Xofigo) for patients with metastatic castration-resistant prostate cancer (mCRPC).
Radium-223 makes for an interesting compound because, unlike many other therapies in the field, it is not androgen receptor (AR)-directed, Dreicer explains. The agent is approved before or after treatment with docetaxel for patients with predominant bone metastases. Because of this, it is a useful therapy for select patients.
Currently, researchers are questioning how to properly integrate radium-223 with AR therapies. Therefore, the optimal use of radium-223 in patients with mCRPC is not yet defined, Dreicer concludes.
<<<
